Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

This study is testing a combination of selinexor (a drug that blocks a protein called XPO1) with standard chemotherapy (COPL regimen) for patients newly diagnosed with advanced NK/T-cell lymphoma, a rare type of blood cancer more common in Asia. The goal is to see if adding selinexor improves response rates and survival. **You may be eligible if...** - You are 14 or older with newly diagnosed NK/T-cell lymphoma confirmed by biopsy - Your cancer is at an advanced stage (stage III or IV) - You have at least one measurable tumor site - Your blood counts and organ function meet required levels - Your expected survival is greater than 6 months **You may NOT be eligible if...** - You have previously had a bone marrow transplant from a donor - You have an active autoimmune disease - Your cancer has spread to the brain - You have HIV or an active serious infection - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.